Your browser doesn't support javascript.
loading
Treatment of acute cholestatic hepatitis by Compound Yindan Decoction: a clinical observation / 中国中西医结合杂志
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-297434
Responsible library: WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To observe the clinical efficacy of comprehensive Western medical treatment plus Compound Yindan Decoction (CYD) in treatment of acute cholestatic hepatitis (ACH).</p><p><b>METHODS</b>Using randomized controlled study, 60 ACH patients in line with inclusive criteria were randomly assigned to the treatment group (treated by comprehensive Western medical treatment plus CYD) and the control group (treated by comprehensive Western medical treatment alone), 30 in each group. Scores for symptoms and levels of liver functions [total bilirubin (TBIL), direct bilirubin (DBIL), alkaline phosphatase (ALP), glutamyl transpeptidase (GGT), total biliary acid (TBA)] were observed before and after treatment.</p><p><b>RESULTS</b>Compared with before treatment in the same group, total scores for symptoms decreased in the treatment group and the control group at the end of the 1st and the 4th week after treatment (all P < 0.05). Compared with the control group, total scores for symptoms decreased in the treatment group at the end of the 1st week (P < 0.05). Compared with before treatment, serum levels of TBIL, DBIL, ALP, GGT, and TBA all decreased in the two groups at the end of the 4th week after treat- ment (P < 0.01). Compared with the control group, serum levels of TBIL, DBIL, ALP, GGT, and TBA all decreased in the treatment group at the end of the 1st and the 2nd week after treatment (P < 0.05). Compared with the control group, the average time for TBIL and DBIL decreasing to the level less than five times the normal value was significantly shorter in the treatment group (P < 0.05).</p><p><b>CONCLUSION</b>CYD could significantly improve clinical symptoms of ACH patients, decrease serum levels of TBIL and DBIL, reduce serum levels of ALP, GGT, and TBA, obviously improve cholestasis, and promote the recovery.</p>
Subject(s)
Full text: Available Health context: SDG3 - Health and Well-Being Health problem: Target 3.3: End transmission of communicable diseases Database: WPRIM (Western Pacific) Main subject: Bilirubin / Drugs, Chinese Herbal / Cholestasis / Combined Modality Therapy / Therapeutic Uses / Drug Therapy / Alkaline Phosphatase / Gamma-Glutamyltransferase / Hepatitis Type of study: Controlled clinical trial Limits: Humans Language: Chinese Journal: Chinese Journal of Integrated Traditional and Western Medicine Year: 2015 Document type: Article
Full text: Available Health context: SDG3 - Health and Well-Being Health problem: Target 3.3: End transmission of communicable diseases Database: WPRIM (Western Pacific) Main subject: Bilirubin / Drugs, Chinese Herbal / Cholestasis / Combined Modality Therapy / Therapeutic Uses / Drug Therapy / Alkaline Phosphatase / Gamma-Glutamyltransferase / Hepatitis Type of study: Controlled clinical trial Limits: Humans Language: Chinese Journal: Chinese Journal of Integrated Traditional and Western Medicine Year: 2015 Document type: Article
...